Abstract
Golgi protein 73 (GP73) is a type II Golgi transmembrane protein which is overexpressed in several cancers, however, its role in gastric cancer is still unclear. The aim of this study is to investigate if high GP73 expression is associated with pathological tumor response to neoadjuvant chemotherapy and prognosis for patients with gastric cancer. A total of 348 patients with gastric cancer, who had undergone surgery between 1999 and 2011 were retrospectively reviewed, GP73 expression was examined in tumor tissues using tissue microarray and the correlations between its expression and pathological response to neoadjuvant chemotherapy as well as patients prognosis were analyzed. We found that GP73 expression was not associated with clinicopathologic features including tumor size, differentiation and TNM stage. High expression of GP73 was associated with less pathological tumor response to neoadjuvant chemotherapy and poor survival in gastric cancer, multivariate analysis showed GP73 expression was an independent predictive factor for pathological response to neoadjuvant chemotherapy and for prognosis in patients with gastric cancer. Our results suggest that GP73 expression correlates with the effect of neoadjuvant chemotherapy and is a promising biomarker to identify patients with poor prognosis.
Highlights
Gastric cancer (GC) is the fourth most common cancer and is the second most common cause of death from cancer in the world
Golgi protein 73 (GP73) expression was determined by IHC in 348 gastric cancer tissues on the tissue microarray (TMA)
Patients with larger tumor size were more likely to have high GP73 expression than those with small tumor size (p 0.014), other clinicopathologic parameters including age, tumor location, differentiation, peritoneal metastasis and TNM stage were not associated with the GP73 expression level
Summary
Gastric cancer (GC) is the fourth most common cancer and is the second most common cause of death from cancer in the world. It is estimated that two-thirds of gastric cancer cases occur in developing countries and 42% in China alone [1, 2]. The 5-years survival rate for patients with all stages stays ∼20% [3]. It is essential to develop effective prognostic factors that may predict patient survival in gastric cancer. Preoperative chemotherapy is widely used in patients with locally advanced gastric cancer, since it can improve complete surgical resection so as to improve survival [4]. The effect of neoadjuvant chemotherapy stays at 50%, in unresponsive cases, it may have potential to delay
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
